Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Completed · Phase 2
Conditions studied: Squamous Cell Carcinoma of the Head and Neck
In brief
Dalantercept, a soluble form of the activin receptor-like kinase-1 protein, is being studied in patients with squamous cell carcinoma of the head and neck (SCCHN). Dalantercept blocks the development of blood vessels that supply tumors.
Key facts
- Study ID
- NCT01458392
- Run by
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- People needed
- 46
- Starts
- 2011-10-01
- Expected to finish
- 2015-09-01
- Last updated by the study team
- 2022-10-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Acceleron Investigative Site — Aurora, Colorado, United States
- Acceleron Investigative Site — Atlanta, Georgia, United States
- Acceleron Investigative Site — Boston, Massachusetts, United States
- Acceleron Investigative Site — Detroit, Michigan, United States
- Acceleron Investigative Site — New York, New York, United States
- Acceleron Investigative Site — Philadelphia, Pennsylvania, United States
- Acceleron Investigative Site — San Antonio, Texas, United States
- Acceleron Investigative Site — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.